The Federal Trade Commission is targeting brand-name drugmakers that are improperly listing patents, which can weaken competition.
Read the full post on Becker's Hospital Review - Healthcare News
FTC cracks down on improper drug patent filings
The Federal Trade Commission is targeting brand-name drugmakers that are improperly listing patents, which can weaken competition.
Read the full post on Becker's Hospital Review - Healthcare News